8,952 results on '"Cutaneous T-cell lymphoma"'
Search Results
2. Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
- Published
- 2024
3. A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
- Published
- 2024
4. Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL
- Author
-
Carlos III Health Institute
- Published
- 2024
5. Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
- Published
- 2024
6. Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
- Author
-
Kyowa Hakko Kirin Pharma, Inc.
- Published
- 2024
7. A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
- Published
- 2024
8. A dramatic case of oral epitheliolysis.
- Author
-
Fatahzadeh, Mahnaz and Suster, David
- Subjects
CHEMICAL burns ,DEXAMETHASONE ,ORAL diseases ,DIFFERENTIAL diagnosis ,ASPIRIN ,MASTICATION ,ORAL mucosa ,EPITHELIAL cells ,CUTANEOUS T-cell lymphoma - Abstract
Oral epitheliolysis or mucosal shedding is an infrequently described phenomenon characterized by epithelial desquamation, revealing mucosa of normal color and texture underneath. The condition has a predilection for middle-aged females and primarily affects nonkeratinized oral tissues. Although some cases are idiopathic, certain oral hygiene products have been implicated as the culprit, and resolution of the condition documented with their discontinuation. Severity of desquamation and symptoms vary with frequency and duration of contact with the irritant and its concentration. A case is presented of a dramatic case of shedding oral mucosa in an elderly female, which appeared to be caused by habitual chewing of an aspirincontaining over-the-counter analgesic. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
- Published
- 2024
10. Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- Author
-
Oleg E. Akilov, MD, PhD, Assistant Professor of Dermatology
- Published
- 2024
11. A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma.
- Author
-
Kuruvilla, John, Rushton, Christopher, Villa, Diego, Aslam, Muhammad, Prica, Anca, Abdel Samad, Nizar, Doucet, Stephane, Dudebout, Jill, Fleury, Isabelle, Fraser, Graeme, Larouche, Jean‐Francois, Shafey, Mona, Skrabek, Pamela, Skamene, Tanya, Morin, Ryan D., Alcaide, Miguel, Ben‐Neriah, Susana, Lee, David, Winch, Chad, and Shepherd, Lois E.
- Subjects
- *
BRUTON tyrosine kinase , *HODGKIN'S disease , *B cell receptors , *B cell lymphoma , *FLUORESCENCE in situ hybridization , *CUTANEOUS T-cell lymphoma , *DIFFUSE large B-cell lymphomas - Abstract
This article summarizes a randomized trial that evaluated the effectiveness of a combination therapy for relapsed diffuse large B-cell lymphoma (DLBCL) prior to stem cell transplant. The trial compared the response rates and outcomes of patients who received the combination therapy with those who received chemotherapy alone. The results showed that the response rate was higher in the chemotherapy group, leading to the discontinuation of the combination therapy. The study also analyzed the genetic subtypes of DLBCL and found that certain patients responded better to the combination therapy. The article emphasizes the need for biomarker-driven trials and comprehensive studies in therapeutic trials for DLBCL. The trial was supported by funding from various organizations. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
12. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas.
- Author
-
Swallow, Madisen A., Micevic, Goran, Zhou, Amanda, Carlson, Kacie R., Foss, Francine M., and Girardi, Michael
- Subjects
- *
T cells , *MYCOSIS fungoides , *CUTANEOUS T-cell lymphoma , *IMMUNOHISTOCHEMISTRY , *HISTOLOGICAL techniques , *LYMPHOPROLIFERATIVE disorders , *CELL differentiation , *STAINS & staining (Microscopy) , *PHENOTYPES - Abstract
Simple Summary: CD8+ CTCL subtypes manifest with widespread clinical, histologic, and phenotypic features that inform the classification of the disease. Through this review, we highlight the importance of utilizing the synergy of clinical, histologic, and immunohistochemical findings to determine a correct diagnosis and applicable treatment plan. Although the vast majority of CTCL subtypes are of the CD4+ T-helper cell differentiation phenotype, there is a spectrum of CD8+ variants that manifest wide-ranging clinical, histologic, and phenotypic features that inform the classification of the disease. CD8, like CD4, and cytotoxic molecules (including TIA and granzyme) are readily detectable via IHC staining of tissue and, when expressed on the phenotypically abnormal T-cell population, can help distinguish specific CTCL subtypes. Nonetheless, given that the histopathologic differential for CD8+ lymphoproliferative disorders and lymphomas may range from very indolent lymphomatoid papulosis (LyP) to aggressive entities like CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (AECTCL), CD8 and/or cytotoxic molecule expression alone is insufficient for diagnosis and is not in itself an indicator of prognosis. We present a review of CTCL subtypes that can demonstrate CD8 positivity: CD8+ mycosis fungoides (MF), LyP type D, subcutaneous panniculitis-like T-cell lymphoma (SPTCL), primary cutaneous gamma/delta T-cell lymphoma (PCGDTL), CD8+ AECTCL, and acral CD8+ T-cell lymphoproliferative disorder (acral CD8+ TCLPD). These diseases may have different clinical manifestations and distinctive treatment algorithms. Due to the rare nature of these diseases, it is imperative to integrate clinical, histologic, and immunohistochemical findings to determine an accurate diagnosis and an appropriate treatment plan. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Estimation of the tissue and serum levels of IL-35 in Mycosis fungoides: a case-control study.
- Author
-
Elmasry, Maha Fathy, Obaid, Yasmine Ahmed, El-Samanoudy, Solwan Ibrahim, Nour, Zeinab Ahmed, and Doss, Sally Sameh
- Subjects
- *
MYCOSIS fungoides , *CUTANEOUS T-cell lymphoma , *CASE-control method , *DISEASE relapse , *SKIN biopsy , *TISSUES - Abstract
Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL) with its etiology not yet fully understood. Interleukin (IL)-35 is an inhibitory cytokine that belongs to the IL-12 family. Elevated IL-35 in the plasma and the tumor microenvironment increases tumorigenesis and indicates poor prognosis in different types of malignancies. The objective of this study is to estimate the expression levels of IL-35 in tissue and serum of MF patients versus healthy controls. This case-control study included 35 patients with patch, plaque, and tumor MF as well as 30 healthy controls. Patients were fully assessed, and serum samples and lesional skin biopsies were taken prior to starting treatment. The IL-35 levels were measured in both serum and tissue biopsies by ELISA technique. Both tissue and serum IL-35 levels were significantly higher in MF patients than in controls (P < 0.001) and tissue IL-35 was significantly higher than serum IL-35 in MF patients (P < 0.001). Tissue IL-35 was significantly higher in female patients and patients with recurrent MF compared to male patients and those without recurrent disease (P < 0.001). Since both tissue and serum IL-35 levels are increased in MF, IL-35 is suggested to have a possible role in MF pathogenesis. IL-35 can be a useful diagnostic marker for MF. Tissue IL-35 can also be an indicator of disease recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature.
- Author
-
Silva, Genevieve S., Kim, Ellen J., Barta, Stefan K., and Chung, Jina
- Subjects
REGULATORY T cells ,DRUG side effects ,T-cell lymphoma ,LITERATURE reviews ,IMMUNE checkpoint inhibitors ,CUTANEOUS T-cell lymphoma - Abstract
Mogamulizumab is an anti-C–C chemokine receptor 4 antibody that is increasingly being used to treat T-cell malignancies such as cutaneous T-cell lymphoma, adult T-cell leukemia-lymphoma, and peripheral T-cell lymphoma. Because CCR4 is expressed on both malignant T-cells and regulatory T-cells (Tregs), mogamulizumab can be associated with increased immune-related adverse events (irAEs). While there is abundant literature on mogamulizumab-associated rash (MAR) and graft-versus-host disease (GVHD), other reported irAEs have not been collated into a single review. This narrative review covers irAEs associated with mogamulizumab in patients with T-cell lymphomas, focusing on events other than MAR and GVHD. We searched PubMed and Google Scholar for case reports, case series, chart reviews, and clinical trials published from inception to March 2024. Identified events include alopecia, vitiligo, arthritis, psoriasis, myocarditis, myositis/polymyositis, hepatitis, and others. Mogamulizumab's ability to augment the host immune response through Treg depletion adds to its efficacy but has wide-ranging implications for autoimmunity across multiple organ systems, similar to immune checkpoint inhibitor therapy. Occurrence of irAEs may be associated with improved overall clinical response, although long-term follow-up studies are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Prevalence, clinical features, and survival outcome trends of 627 patients with primary cutaneous lymphoma over 29 years: a retrospective review from single tertiary center in Korea.
- Author
-
Moon, Ik Jun, Won, Chong Hyun, Chang, Sung Eun, Park, Chan-Sik, Yoon, Dok-Hyun, Song, Si Yeol, Lee, Mi Woo, and Lee, Woo Jin
- Subjects
- *
SURVIVAL rate , *CUTANEOUS T-cell lymphoma , *T-cell lymphoma , *MUCOSA-associated lymphoid tissue lymphoma , *MYCOSIS fungoides , *B cells - Abstract
The relative frequency of primary cutaneous lymphoma (PCL) subtypes shows wide variation across different geographical regions. This retrospective study was conducted in a tertiary referral center located in Korea to describe the relative frequency, demographics, survival outcomes, and temporal trend in PCL. A total of 627 PCL cases diagnosed between January 1994 and December 2022 were included. The majority of PCL cases (87.2%) were of T-/NK-cell lineage (CTCL), while the remaining cases (12.8%) were B-cell lineage lymphomas (CBCL). The prevalence of mycosis fungoides (MF) in CTCL increased significantly over time, while other CTCL subtypes, including primary cutaneous extranodal NK/T-cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma (SPTCL), decreased in frequency. Notably, the prevalence of CD4-positive small/medium T-cell lymphoproliferative disorder showed a substantial increase over time. Primary cutaneous marginal zone lymphoma was consistently the commonest CBCL subtype. Survival analysis demonstrated that CTCL had a more favorable 5-year overall survival (OS) than CBCL. OS rate of MF, SPTCL, and primary cutaneous peripheral T-cell lymphoma, NOS improved significantly over time. This study provides comprehensive insights into the dynamic change in the relative frequency and overall survival of PCL subtypes over time. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Correction: Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International Consensus Classification.
- Author
-
Ferry, Judith A., Hill, Brian, and Hsi, Eric D.
- Subjects
- *
DIFFUSE large B-cell lymphomas , *MUCOSA-associated lymphoid tissue lymphoma , *CUTANEOUS T-cell lymphoma , *PLASMA cells , *LYMPHOCYTIC leukemia , *HODGKIN'S disease ,CENTRAL nervous system tumors - Abstract
This document is a correction notice for an article on the classification of mature B, T, and NK-cell neoplasms. The original article had errors in Table 1, which have been corrected in this document. The corrected table compares the classification of different types of lymphomas according to various classifications. The document provides a comprehensive overview of the different types of lymphomas, including subtypes of large B-cell lymphomas and other types associated with immune deficiency and dysregulation. It aims to provide accurate information for library patrons conducting research on these specific topics. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
17. Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature.
- Author
-
Srinivas, Nalini, Peiffer, Lukas, Horny, Kai, Kuan Cheok Lei, Buus, Terkild B., Kubat, Linda, Meng Luo, Menghong Yin, Spassova, Ivelina, Sucker, Antje, Farahpour, Farnoush, Kehrmann, Jan, Ugurel, Selma, Livingstone, Elisabeth, Gambichler, Thilo, Ødum, Niels, and Becker, Jürgen C.
- Subjects
CYTOTOXIC T cells ,CUTANEOUS T-cell lymphoma ,DRUG eruptions ,CANCER cells ,T cells ,MYCOSIS fungoides - Abstract
Background: Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL). Comprehensive analysis of MF cells in situ and ex vivo is complicated by the fact that is challenging to distinguish malignant from reactive T cells with certainty. Methods: To overcome this limitation, we performed combined single-cell RNA (scRNAseq) and T-cell receptor TCR sequencing (scTCRseq) of skin lesions of cutaneous MF lesions from 12 patients. A sufficient quantity of living T cells was obtained from 9 patients, but 2 had to be excluded due to unclear diagnoses (coexisting CLL or revision to a fixed toxic drug eruption). Results: From the remaining patients we established single-cell mRNA expression profiles and the corresponding TCR repertoire of 18,630 T cells. TCR clonality unequivocally identified 13,592 malignant T cells. Reactive T cells of all patients clustered together, while malignant cells of each patient formed a unique cluster expressing genes typical of naive/memory, such as CD27, CCR7 and IL7R, or cytotoxic T cells, e.g., GZMA, NKG7 and GNLY. Genes encoding classic CTCL markers were not detected in all clusters, consistent with the fact that mRNA expression does not correlate linearly with protein expression. Nevertheless, we successfully pinpointed distinctive gene signatures differentiating reactive malignant from malignant T cells: keratins (KRT81, KRT86), galectins (LGALS1, LGALS3) and S100 genes (S100A4, S100A6) being overexpressed in malignant cells. Conclusions: Combined scRNAseq and scTCRseq not only allows unambiguous identification of MF cells, but also revealed marked heterogeneity between and within patients with unexpected functional phenotypes. While the correlation between mRNA and protein abundance was limited with respect to established MF markers, we were able to identify a single-cell gene expression signature that distinguishes malignant from reactive T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Exploring the educational needs of patients with cutaneous lymphoma using an educational needs assessment tool.
- Author
-
Ivert, Lina U., Winther, Anna H., Jonsson, Pontus, and Brauner, Hanna
- Subjects
CUTANEOUS T-cell lymphoma ,PATIENT education ,MYCOSIS fungoides ,MEDICAL personnel ,SUPPORT groups - Abstract
Background: Cutaneous T-cell lymphomas (CTCL) are a group of rare non-Hodgkin lymphomas characterized by initial localization of malignant T- lymphocytes in the skin. Support and information from nurses and patient support groups have proven useful for patients with CTCL, but little is known about the educational needs of these patients. Objectives: To investigate the self-reported educational needs among CTCL patients using an educational needs assessment tool and to explore differences related to sex, age, disease duration, clinical stage, and education. Methods: This observational single center study analyzed 70 patients with CTCL in routine dermatological outpatient care. The patients were asked to complete a questionnaire to capture their educational needs in regard to CTCL. The questionnaire was inspired by the educational needs assessment tool, designed and validated for patients with rheumatoid disease. The questionnaire included a general question, "In general, how much information do you want to receive about your lymphoma disease?", and five domains covering information relating to disease process (6 items), treatment (4 items), feelings (2 items), self-management of itch, sleep, and rest (2 items), and support systems (3 items). The domain scores ranged from 0 to 18 and the total score from 0 to 51, with a higher score indicating a greater need for education. Results: When asked "In general, how much information do you need?", females wanted to know more compared with males (2.6 vs. 2.1, p=0.006), and patients with higher education wanted to know more than patients with lower education (2.5 vs. 2.0, p=0.025). The domains concerning treatment (80%) and disease process (75%) revealed the greatest needs for education. Patients with a disease duration <2 years reported a greater educational need for the domain support system, compared with patients with longer disease duration. Patients with lower education reported a greater educational need about feelings compared with patients with higher education. Conclusions: We found that 65% of the CTCL patients in the cohort, particularly females, expressed a need for education, especially regarding disease process and treatment. A deeper understanding of the educational needs would enable healthcare providers to give personalized information. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Single nucleotide polymorphism profiles of canine T-cell and null-cell lymphomas.
- Author
-
Sirivisoot, Sirintra, Kasantikul, Tanit, Techangamsuwan, Somporn, and Rungsipipat, Anudep
- Subjects
SINGLE nucleotide polymorphisms ,T-cell lymphoma ,LYMPHOMAS ,GENETIC profile ,CUTANEOUS T-cell lymphoma ,TOOTH transposition ,BRAF genes - Abstract
Background: The histopathological classification of T-cell lymphoma (TCL) in humans has distinctive mutational genotyping that suggests different lymphomagenesis. A similar concept is assumed to be observed in dogs with different TCL phenotypes. Objective: This study aimed to identify the previously reported single-nucleotide polymorphisms (SNPs) in both human beings and dogs in canine TCLs and nullcell lymphomas (NCLs) and to design compatible oligonucleotides from each variant based on the multiplex polymerase chain reaction. Methods: Genomic DNA was extracted from 68 tumor specimens (62 TCLs and 6 NCLs) and 5 buffy coat samples from dogs with TCL. Four TCL subtypes and NCL were analyzed in 44 SNPs from 21 genes using the MassARRAY. Results: The greatest incidences of SNPs observed in all TCL subtypes and NCL ware SATB1 c.1259A > C, KIT c.1275A > G, SEL1L c.2040 + 200C > G, and TP53 c.1024C > T, respectively. Some SNP locations were statistically significant associated with NCL, including MYC p.S75F (p = 0.0003), TP53 p.I149N (p = 0.030), PDCD1 p.F37LX (p = 0.012), and POT1 p.R583* (p = 0.012). Conclusion: Each TCL histological subtype and NCL are likely to contain distinctive mutational genetic profiles, which might play a role in lymphoma gene-risk factors and might be useful for selecting therapeutic target drugs for each canine patient. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Beyond the pale: Insights into hypopigmented mycosis fungoides -- A case report.
- Author
-
Zauddin, Nur Zafirah and Hadi, Azwanis Abdul
- Subjects
- *
CUTANEOUS T-cell lymphoma , *NON-Hodgkin's lymphoma , *SKIN infections , *MYCOSES , *SKIN biopsy , *SEZARY syndrome - Abstract
Hypopigmented mycosis fungoides (MF) is a rare variant of cutaneous T-cell lymphoma, a type of extranodal non-Hodgkin lymphoma. This report presents the case of a 9-year-old boy with a 2-year history of asymptomatic, hypopigmented skin lesions that were resistant to topical treatment. He was initially treated for a fungal skin infection and had received multiple courses of topical antifungals and steroids but showed no improvement, which led to further evaluation and a referral to a dermatologist. A skin biopsy was performed, and the diagnosis of hypopigmented MF was confirmed through skin histopathology and immunohistochemistry study. His lesions responded well to cycles of narrowband ultraviolet B phototherapy, showing almost complete clearance after 4 months without any side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Stage‐related increase in PIM2 expression in mycosis fungoides.
- Author
-
Nielsen, Mie Holm, Nielsen, Pia Rude, Bzorek, Michael, Eriksen, Jens Ole, Wehkamp, Ulrike, Lindahl, Lise Maria, Woetmann, Anders, Ødum, Niels, Litman, Thomas, and Gjerdrum, Lise Mette Rahbek
- Subjects
- *
MYCOSIS fungoides , *GENE expression , *CUTANEOUS T-cell lymphoma , *IMMUNOSTAINING , *SKIN biopsy - Abstract
The oncogene PIM2 is upregulated in several malignancies but has never been investigated in mycosis fungoides (MF), the most common type of cutaneous T‐cell lymphoma (CTCL). PIM2 is a well‐known oncogene and is regulated by cell signaling pathways like the JAK/STAT‐ and NF‐kB‐pathway, key regulators in the pathogenesis of CTCL. The aim of this study was to examine the role of PIM2 in MF. PIM2 gene expression was measured in 81 formalin‐fixed paraffin‐embedded skin biopsies from patients with MF and 46 control biopsies from healthy skin (HS) and benign inflammatory skin disease (BID). Validation of PIM2 protein expression was performed on selected biopsies with immunohistochemical staining. We found a significant difference in gene expression levels between both early stage MF and HS (p < 0.0001), and BID (p < 0.0001). In addition, the PIM2 gene expression was higher in advanced‐stage MF compared to early stage disease (p = 0.0001). No significant difference in gene expression levels was found between patients with and without disease progression. In conclusion, we found PIM2 expression is significantly increased in MF compared to controls, and in advanced‐stage MF compared to early stage MF. These findings could potentially have diagnostic value in discriminating early stage MF from BID. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Null T‐cell phenotype mycosis fungoides with aberrant CD20 and CD56 expression: A diagnostic dilemma.
- Author
-
Aran, Brenna M., Burton, Regina, High, Whitney A., and Gru, Alejandro A.
- Subjects
- *
MYCOSIS fungoides , *CUTANEOUS T-cell lymphoma , *CD20 antigen , *PHENOTYPES , *BODY surface area , *B cells , *T cells , *ARTIFICIAL hip joints - Abstract
Mycosis fungoides (MF) represents the most common type of primary cutaneous T‐cell lymphoma. Recognition of MF variants with divergent immunophenotypes is important for accurate diagnosis and appropriate management, as they can be confused with other lymphoma subtypes. We present a case of a 49‐year‐old male previously diagnosed with a cutaneous lymphoproliferative disorder with an unusual NK/T‐cell phenotype. He presented with a 10‐year history of pelvic girdle rash involving the right hip and upper thigh. The lesions were characterized as atrophic patches concentrated in sun‐protected areas and involving 10% of the body surface area. Shave biopsies revealed an atypical epidermotropic infiltrate composed of hyperchromatic small to medium‐sized lymphocytes with perinuclear halos and "tagging" along the dermal–epidermal junction. The immunophenotype was unusual in that the neoplastic lymphocytes showed complete loss of pan T‐cell antigens along with expression of CD56, cytotoxic markers, and weak CD20. All other B‐cell markers were negative. The combination of clinical findings, in addition to the histopathologic and immunophenotypic profile, were diagnostic of null T‐cell phenotype MF with aberrant expression of CD56 and CD20. Null T‐cell phenotype MF is very uncommon, can be diagnostically challenging, and can mislead the diagnosis of aggressive lymphoma subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma.
- Author
-
Angelova, Assia, Barf, Milena, Just, Alexandra, Leuchs, Barbara, Rommelaere, Jean, and Ungerechts, Guy
- Subjects
- *
ADENOSINE triphosphate metabolism , *ONCOLYTIC virotherapy , *NON-Hodgkin's lymphoma , *RESEARCH funding , *PILOT projects , *CUTANEOUS T-cell lymphoma , *RATS , *CELL lines , *GENE expression , *ANIMAL experimentation , *CELL survival , *PARVOVIRUS diseases , *CELL receptors - Abstract
Simple Summary: Cutaneous T-cell lymphoma (CTCL) is a rare type of T-lymphocyte malignancy strongly calling for novel therapies. Virotherapy by means of oncolytic viruses that are able to kill cancer cells, while sparing healthy cells, is a promising innovative form of anticancer immunotherapy. The aim of this study was to investigate the potential of an oncolytic parvovirus, H-1PV, to induce selective killing (oncolysis) of CTCL cells and suppress the growth of CTCL spheroids. We demonstrated that H-1PV treatment led to oncolysis in tumor, but not in control normal cells. Oncolysis ensued despite pro-survival protein overexpression and was associated with the release of danger-signaling molecules. In heterotypic CTCL spheroids, H-1PV induced spheroid growth suppression and, upon co-culturing with peripheral blood mononuclear cells, spheroid infiltration with immune cells. In summary, we gathered the first preclinical data showing that H-1PV holds significant potential to become a novel viroimmunotherapeutic agent against CTCL. The rat protoparvovirus H-1 (H-1PV) is an oncolytic virus known for its anticancer properties in laboratory models of various human tumors, including non-Hodgkin lymphomas (NHL) of B-cell origin. However, H-1PV therapeutic potential against hematological malignancies of T-cell origin remains underexplored. The aim of the present study was to conduct a pilot preclinical investigation of H-1PV-mediated oncolytic effects in cutaneous T-cell lymphoma (CTCL), a type of NHL that is urgently calling for innovative therapies. We demonstrated H-1PV productive infection and induction of oncolysis in both classically grown CTCL suspension cultures and in a novel, in vivo-relevant, heterotypic spheroid model, but not in healthy donor controls, including peripheral blood mononuclear cells (PBMCs). H-1PV-mediated oncolysis of CTCL cells was not prevented by Bcl-2 overexpression and was accompanied by increased extracellular ATP release. In CTCL spheroid co-cultures with PBMCs, increased spheroid infiltration with immune cells was detected upon co-culture treatment with the virus. In conclusion, our preclinical data show that H-1PV may hold significant potential as an ingenious viroimmunotherapeutic drug candidate against CTCL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Neurolymphomatosis as primary presentation of extra-nodal NK/T-cell lymphoma, nasal type.
- Author
-
Silva, Maria Inês, Santos, Pedro, Viegas, Diana, Miranda, Miguel, Montes, Vera, Pita, Fernando, and Carmona, Cátia
- Subjects
- *
CUTANEOUS T-cell lymphoma , *PERIPHERAL nervous system , *MAGNETIC resonance imaging , *POSITRON emission tomography , *LYMPHOMAS , *CENTRAL nervous system - Abstract
Neurolymphomatosis (NL) describes an infiltration of cranial and peripheral nerves by lymphoma cells, most frequently in non-Hodgkin B-cell lymphoma. This clinical entity is rare and poses a challenging diagnosis. We describe a case of a 64-year-old female patient with NL associated with extra-nodal NK/T-cell lymphoma (ENKTL), nasal type, presenting as a painful progressive mononeuropathy multiplex with an oral cavity lesion. ENKTL is usually associated with Epstein-Barr virus (EBV) infection and rarely affects the central and peripheral nervous system. Lumbar puncture, magnetic resonance imaging (MRI), nerve biopsy, and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) help to establish the diagnosis. Thereby, NL should be considered in the differential diagnosis of painful progressive multiple neuropathies, even in patients without previous history of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Spatiotemporal changes and functional alterations of T-cell substates gene expression during the progression of mycosis fungoides.
- Author
-
Dong, Zhengbang, Zhu, Xinyu, Pan, Xiaoyuan, Su, Qianya, and Wang, Fei
- Subjects
- *
SEZARY syndrome , *MYCOSIS fungoides , *T cells , *GENE expression , *CUTANEOUS T-cell lymphoma , *REGULATORY T cells - Abstract
This document is a letter published in the Archives of Dermatological Research. The letter discusses the spatiotemporal changes and functional alterations of T-cell substates gene expression during the progression of mycosis fungoides (MF), a type of cutaneous T-cell lymphoma (CTCL). The authors conducted a mass cytometry experiment comparing the proportion difference of T-cell substates in MF patients' skin and lymphatic tissues and peripheral blood. They found that CD8+ T-cell exhaustion and CD4+ T helper cell type-1 (Th1) were significantly higher in skin tissues compared to lymphatic tissues and peripheral blood. The authors also analyzed publicly available single-cell RNA-seq datasets to identify landmark genes affecting the dynamic changes of T-cell substates during the progression of MF. They concluded that this study expands our understanding of MF disease and provides potential biomarkers for future immunotherapy. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
26. Presence of herpesviruses, parvoviruses, and polyomaviruses in sinonasal lymphoma.
- Author
-
Jauhiainen, Maria K., Mohanraj, Ushanandini, Perdomo, Maria F., Hagström, Jaana, Haglund, Caj, Mäkitie, Antti A., Söderlund-Venermo, Maria, and Sinkkonen, Saku T.
- Subjects
- *
PARANASAL sinuses , *HERPESVIRUSES , *DIFFUSE large B-cell lymphomas , *CUTANEOUS T-cell lymphoma , *PARVOVIRUSES , *MOLECULAR biology - Abstract
Purpose: Sinonasal lymphoma (SL) is a rare lymphatic neoplasm of the nasal cavities, paranasal sinuses and nasopharynx. Whereas some risk factors for SL subtypes have been identified, their aetiology is unknown. Along with other predisposing factors, the viral association of lymphomas, such as Epstein-Barr virus (EBV) and Burkitt and Hodgkin lymphomas, is well-established. Modern molecular biology techniques have enabled the discovery of novel human viruses, exemplified by the protoparvovirus cutavirus (CuV), associated with cutaneous T-cell lymphoma. These findings, and the anatomical location of the sinonasal tract with its rich microbiome and infectious agents, justify in-depth studies among SL. Methods: We analysed the presence of 20 viruses of Orthoherpesviridae, Parvoviridae, and Polyomaviridae by qPCR in 24 SL tumours. We performed RNAscope in situ hybridisation (RISH) to localize the viruses. Parvovirus-specific IgG was analysed by enzyme immunoassay and targeted next-generation sequencing (NGS) was applied to detect CuV in plasma. Results: We detected viral DNA in 15/24 (63%) tumours; nine of EBV, six of human herpesvirus (HHV) -7, four each of HHV-6B and parvovirus B19, two of cytomegalovirus, and one each of CuV and Merkel-cell polyomavirus. We found tumours with up to four viruses per tumour, and localized CuV and EBV DNAs by RISH. Two of the ten plasma samples exhibited CuV IgG, and one plasma sample demonstrated CuV viremia by NGS. Conclusion: Viruses were frequent findings in SL. The EBV detection rate was high in diffuse large B-cell lymphoma, and co-detections with other viruses were prevalent. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group.
- Author
-
Kempf, W., Mitteldorf, C., Cerroni, L., Willemze, R., Berti, E., Guenova, E., Scarisbrick, J. J., and Battistella, M.
- Subjects
- *
CUTANEOUS T-cell lymphoma , *LYMPHOPROLIFERATIVE disorders , *MUCOSA-associated lymphoid tissue lymphoma , *T-cell lymphoma , *LYMPHOMAS , *CLASSIFICATION - Abstract
The classification of primary cutaneous lymphomas and lymphoproliferative disorders (LPD) is continuously evolving by integrating novel clinical, pathological and molecular data. Recently two new classifications for haematological malignancies including entities of cutaneous lymphomas were proposed: the 5th edition of the WHO classification of haematolymphoid tumours and the International Consensus Classification (ICC) of mature lymphoid neoplasms. This article provides an overview of the changes introduced in these two classifications compared to the previous WHO classification. The main changes shared by both classifications include the downgrading of CD8+ acral T‐cell lymphoma to CD8+ acral T‐cell LPD, and the recognition of entities that were previously categorized as provisional and have now been designated as definite types including primary cutaneous small or medium CD4+ T‐cell LPD, primary cutaneous gamma/delta T‐cell lymphoma, primary cutaneous CD8+ aggressive epidermotropic cytotoxic T‐cell lymphoma, Epstein–Barr virus‐positive mucocutaneous ulcer. Both classifications consider primary cutaneous marginal zone B‐cell clonal neoplasm as an indolent disease but use a different terminology: primary cutaneous marginal zone lymphoma (WHO) and primary cutaneous marginal zone LPD (ICC). The 5th WHO classification further introduces and provides essential and desirable diagnostic criteria for each disease type and includes chapters on reactive B‐ or T‐cell rich lymphoid proliferations formerly referred as cutaneous pseudolymphomas, as well as histiocyte and CD8 T‐cell rich LPD in patients with inborn error of immunity. As already emphasized in previous lymphoma classifications, the importance of integrating clinical, histological, phenotypic and molecular features remains the crucial conceptual base for defining cutaneous (and extracutaneous) lymphomas. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. The unexpected guest: Cytotoxic, pseudolymphoma‐like reaction at the site of primary cutaneous follicle centre B‐cell lymphoma in a patient receiving secukinumab for psoriasis.
- Author
-
Pescia, C., Pini, G., Tabano, S., Berti, E., Alberti Violetti, S., and Croci, G. A.
- Subjects
- *
CUTANEOUS T-cell lymphoma , *TUMOR-infiltrating immune cells , *CYTOTOXIC T cells - Abstract
This article presents a unique case of a patient with primary cutaneous follicle centre B-cell lymphoma (PCFCCL) who developed a T-cell pseudolymphoma while receiving secukinumab for psoriasis treatment. The patient initially received local radiotherapy for PCFCCL and subsequently developed psoriasis. After starting secukinumab, the patient experienced rapid growth and ulceration of the previously irradiated lesion, which was biopsied and revealed a residual PCFCCL component along with a dense proliferation of small-to-medium-sized lymphocytes. The authors suggest that the pseudolymphoma may have been triggered by secukinumab. This case highlights the complex interplay between tumor and self-immunity and the role of lymphoma-specific T cells. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
29. Immunobiology and treatment of cutaneous T-cell lymphoma.
- Author
-
Goel, Rishi R. and Rook, Alain H.
- Subjects
CUTANEOUS T-cell lymphoma ,MYCOSIS fungoides ,LYMPHOPROLIFERATIVE disorders ,T cells ,IMMUNOLOGY ,CANCER cells - Abstract
Primary cutaneous T cell lymphomas (CTCL) are a heterogenous group of non-Hodgkin lymphomas derived from skin-homing T cells. These include mycosis fungoides and its leukemic variant Sezary syndrome, as well as the CD30+ lymphoproliferative disorders. In this review, we provide a summary of the current literature on CTCL, with a focus on the immunopathogenesis and treatment of mycosis fungoides and Sezary syndrome. Recent advances in immunology have provided new insights into the biology of malignant T cells. This in turn has led to the development of new therapies that modulate the immune system to facilitate tumor clearance or target specific aspects of tumor biology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30‐positive cutaneous T‐cell lymphoma.
- Author
-
Hirai, Yoji, Sakurai, Jun, Yoshida, Shiho, Kikuchi, Takashi, Mitsuhashi, Toshiharu, Miyake, Tomoko, Fujimura, Taku, Abe, Riichiro, Fujikawa, Hiroki, Boki, Hikari, Suga, Hiraku, Shibata, Sayaka, Miyagaki, Tomomitsu, Shimauchi, Takatoshi, Kiyohara, Eiji, Kawakami, Yoshio, and Morizane, Shin
- Abstract
Brentuximab vedotin (BV), a conjugate of anti‐CD30 antibody and monomethyl auristatin E, has emerged as a promising treatment option for refractory CD30+ mycosis fungoides (MF) and primary cutaneous anaplastic large‐cell lymphoma (pcALCL). BV has been shown to be safe and effective in treating Hodgkin's lymphoma and peripheral T‐cell lymphoma. This multicenter, prospective, single‐arm phase I/II study evaluated the efficacy of BV in Japanese patients with CD30+ cutaneous lymphomas, namely CD30+ cutaneous T‐cell lymphoma. Participants were divided into two groups: those with CD30+ MF or pcALCL (cohort 1, n = 13) and those with CD30+ lymphoproliferative disorders other than those in cohort 1 (cohort 2, n = 3). The studied population included the full analysis set (FAS), modified FAS (mFAS), and safety analysis set (SAF). These sets were identified in cohorts 1 and 1 + 2 and labeled FAS1 and FAS2, mFAS1 and mFAS2, and SAF1 and SAF2, respectively. Each treatment cycle lasted 3 weeks, and BV was continued for up to 16 cycles after the third cycle based on treatment response. The primary endpoint was the 4‐month objective response rate (ORR4) determined by the Independent Review Forum (IRF). ORR4 was 69.2% for FAS1 and 62.5% for FAS2 (P < 0.0001). Secondary endpoints of ORR, assessed using the global response score (53.8% in FAS1) and modified severity‐weighted assessment tool (62.5% in FAS1), using the IRF, provided results comparable to the primary findings. The incidence of ≥grade 3 adverse events (≥15%) in SAF1 was peripheral neuropathy in three patients (23%) and fever and eosinophilia in two patients (15%). In conclusion, BV showed favorable efficacy, tolerability, and safety profile in Japanese patients with relapsed or refractory CD30+ primary cutaneous T‐cell lymphoma. The trial was registered with University Hospital Medical Information Network Clinical Trials Registry, Japan (protocol ID: UMIN000034205). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.
- Author
-
Hu, Man, Scheffel, Jörg, Frischbutter, Stefan, Steinert, Carolin, Reidel, Ulrich, Spindler, Max, Przybyłowicz, Katarzyna, Hawro, Marlena, Maurer, Marcus, Metz, Martin, and Hawro, Tomasz
- Subjects
- *
SLEEP quality , *MYCOSIS fungoides , *SUBSTANCE P , *MAST cells , *TRYPTASE , *ITCHING , *CUTANEOUS T-cell lymphoma - Abstract
Patients with primary cutaneous T-cell lymphoma (CTCL) often experience severe and difficult-to-treat pruritus that negatively affects their quality of life (QoL). However, the mechanisms of pruritus in CTCL, including mycosis fungoides (MF), remain largely unknown, and detailed characteristics of CTCL-associated pruritus is not fully elucidated. To characterize pruritus in CTCL, cutaneous B-cell lymphoma (CBCL), and large plaque parapsoriasis (LPP), and to identify potential itch mediators involved in the pathogenesis of pruritus in CTCL patients. Clinical data and blood samples were collected from 129 healthy subjects and 142 patients. Itch intensity, QoL impairment, psychological distress, and sleep quality were assessed using validated questionnaires and instruments. Blood levels of BDNF, CCL24, GRP, IL-31, IL-33, sST2, substance P, TSLP, tryptase and total IgE were measured using ELISA or ImmunoCAP. Pruritus was prevalent in CTCL, LPP and CBCL patients, with higher prevalence and severity observed in CTCL. In CTCL, pruritus correlated with significant impairment in QoL, sleep, psychological distress. Compared to healthy controls, elevated levels of IL-31, IL-33, substance P, total IgE, tryptase, and TSLP were found in MF patients. A comparison of MF patients with and without pruritus revealed higher levels of IL-31, substance P, GRP, and CCL24 in the former. Itch intensity positively correlated with IL-31, GRP, CCL24, and tryptase levels. Pruritus significantly burdens CTCL patients, necessitating appropriate therapeutic management. Our findings suggest that various non-histaminergic mediators such as tryptase and IL-31 could be explored as novel therapeutic targets for managing pruritus in MF patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. A case report of solitary presentations of large B-cell lymphoma of immune-privileged sites (IP-LBCL) in the testis, vitreous body, and skin.
- Author
-
Ahn, Jeffrey, Ouyang, Yi, Velasco, Graham, Eapen, Ann, and Ma, Helen
- Subjects
- *
BRUTON tyrosine kinase , *NUCLEOTIDE sequencing , *BIOLOGICAL evolution , *B cell lymphoma , *VITREOUS body , *CUTANEOUS T-cell lymphoma , *DIFFUSE large B-cell lymphomas - Abstract
This letter to the editor discusses a rare case of large B-cell lymphoma (LBCL) in immune-privileged sites, such as the testis, vitreous body, and skin. LBCL in these sites is a rare subgroup with distinct characteristics and a poor prognosis. The patient in this case report had testicular enlargement and later developed involvement in the vitreous body and skin. The diagnosis was confirmed through various tests, and the patient received chemotherapy and radiation therapy. The document also discusses the prevalence of MYD88 mutations in LBCL and the need for further research on disease biology and treatment options for LBCL in immune-privileged sites. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
33. Assessing T‐cell receptor clonality by next‐generation sequencing in atypical cutaneous lymphoid infiltrates and cutaneous T‐cell lymphoma: A scoping review.
- Author
-
Shinohara, Michi M., Rieger, Kerri E., Sundram, Uma, Fung, Maxwell A., and Hristov, Alexandra C.
- Subjects
- *
CUTANEOUS T-cell lymphoma , *NUCLEOTIDE sequencing , *GENE rearrangement , *T-cell receptor genes , *CAPILLARY electrophoresis , *T cells , *B cells - Abstract
The diagnosis of cutaneous T‐cell lymphoma (CTCL) remains challenging. Demonstration of a clonal T‐cell population using T‐cell receptor (TCR) gene rearrangement studies by next‐generation sequencing (NGS) has been explored in several studies. This review summarizes the current literature on NGS‐based sequencing methods for the assessment of TCR clonality in the evaluation of atypical cutaneous lymphoid infiltrates and CTCL on behalf of the American Society of Dermatopathology Appropriate Use Criteria Committee (lymphoproliferative subgroup). PubMed was searched for relevant articles, including CTCL and NGS, for clonality from 1967 to 2022. Thirteen studies were included in the analysis. The skin was the most commonly assayed compartment with TCR NGS. Sensitivity for TCR NGS in the skin ranged between 69% and 100%, compared to 44%–72% for polymerase chain reaction (PCR)‐capillary electrophoresis. Specificity for TCR NGS in the skin ranged from 86% to 100%, compared to 77%–88% for PCR capillary electrophoresis. TCR NGS was also reported to have potential prognostic value in CTCL and can also be used to detect relapse and/or minimal residual disease after treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Reverse causation bias: A simulation study comparing first- and second-line treatments with an overlap of symptoms between treatment indication and studied outcome.
- Author
-
Øland, Christian Bjerregård, Ranch, Lise Skov, Skaaby, Tea, Delvin, Thomas, Jakobsen, Henny Bang, and Pipper, Christian Bressen
- Subjects
- *
CUTANEOUS T-cell lymphoma , *SYMPTOMS , *PROPORTIONAL hazards models - Abstract
Background: Reverse causation is a challenge in many drug-cancer associations, where the cancer symptoms are potentially mistaken for drug indication symptoms. However, tools to assess the magnitude of this type of bias are currently lacking. We used a simulation-based approach to investigate the impact of reverse causation on the association between the use of topical tacrolimus and cutaneous T-cell lymphoma (CTCL) in a multinational, population-based study using topical corticosteroids (TCS) as comparator. Methods: We used a multistate model to simulate patients' use over time of a first- (TCS) and second-line treatment (topical tacrolimus), onset of atopic dermatitis (indication for drugs) and CTCL (the studied outcome). We simulated different scenarios to mimic real-life use of the two treatments. In all scenarios, it was assumed that there was no causal effect of the first- or second-line treatment on the occurrence of CTCL. Simulated data were analysed using Cox proportional hazards models. Results: The simulated hazard ratios (HRs) of CTCL for patients treated with tacrolimus vs. TCS were consistently above 1 in all 9 settings in the main scenario. In our main analysis, we observed a median HR of 3.09 with 95% of the observed values between 2.11 and 4.69. Conclusions: We found substantial reverse causation bias in the simulated CTCL risk estimates for patients treated with tacrolimus vs. TCS. Reverse causation bias may result in a false positive association between the second-line treatment and the studied outcome, and this simulation-based framework can be adapted to quantify the potential reverse causation bias. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing.
- Author
-
Adeuyan, Oluwaseyi, Ouseph, Madhu M., Bao, Liming, Kluk, Michael J., Goldberg, Jonathan S., Geskin, Larisa J., and Magro, Cynthia M.
- Subjects
- *
DIFFUSE large B-cell lymphomas , *CUTANEOUS T-cell lymphoma , *B cell lymphoma , *T-cell receptor genes - Abstract
This article presents a case study of a patient who experienced a late relapse of diffuse large B-cell lymphoma (DLBCL) in the skin after being treated for DLBCL in the testes. The authors highlight the importance of using various diagnostic methods, such as microscopic, phenotypic, molecular, and cytogenetic analysis, to determine whether a late relapse is a clonally related tumor or a clonally unrelated secondary neoplasia. In this case, the study found that the cutaneous lymphoma evolved from the testicular lymphoma, indicating a relapse. The article also discusses the cytogenetic profile of the skin lymphoma and its potential role in determining its location. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
36. Primary cutaneous EBV+ extranodal NK/T‐cell lymphoma of gamma/delta T‐cell lineage in the posttransplantation setting.
- Author
-
Williams, Jessica F., Lucas, Fabienne M., Carrasco, Ruben D., Lovitch, Scott B., Fisher, David C., Kupper, Thomas S., and Sadigh, Sam
- Subjects
- *
LYMPHOMAS , *LYMPHOPROLIFERATIVE disorders , *MYCOSIS fungoides , *CUTANEOUS T-cell lymphoma , *SEZARY syndrome , *T cells - Abstract
Posttransplantation primary cutaneous T‐cell lymphomas (PT‐CTCL) are a rare complication of sustained immunosuppression in the posttransplant setting. When present, PT‐CTCLs are typically EBV− and exhibit features of mycosis fungoides/Sézary syndrome or CD30+ lymphoproliferative disorders. We present a case of a 75‐year‐old individual who developed skin lesions 30 years after liver transplantation. Pathologic evaluation of the skin biopsy revealed involvement by a clonal, EBV+ T‐cell population of gamma/delta lineage with no evidence of systemic disease. Comprehensive genomic profiling was performed, confirming focal one‐copy loss of 6q23.3, altogether consistent with the extremely rare and unusual diagnosis of primary cutaneous EBV+ extranodal NK/T‐cell lymphoma of gamma/delta T‐cell lineage in the posttransplantation setting. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Coexistence of large cell transformed mycosis fungoides and diffuse large B‐cell lymphoma in one patient.
- Author
-
Rohan, Thomas Z., Suriano, Jayson, Tekmen, Volkan, Bhatti, Safiyyah, Talasila, Sahithi, Joffe, Daniel, Holtmeyer, Caleb, Lee, Jason B., Alpdogan, Onder, and Nikbakht, Neda
- Subjects
- *
DIFFUSE large B-cell lymphomas , *MYCOSIS fungoides , *RITUXIMAB , *T cells , *CUTANEOUS T-cell lymphoma , *MYC oncogenes , *NON-Hodgkin's lymphoma , *SKIN tumors - Abstract
Diffuse large B‐cell lymphoma (DLBCL) is the most common and aggressive subtype of non‐Hodgkin lymphoma. The overall risk of developing DLBCL is increased in patients with other lymphomas, such as mycosis fungoides (MF). In this report, we present an 81‐year‐old female with early‐stage MF who simultaneously progressed to tumor stage, large‐cell transformed (LCT) MF and developed a primary DLBCL in a lymph node (LN). She presented with a tumor on her leg and new lymphadenopathy in her right axilla. Skin biopsy of the tumor revealed infiltration of large atypical CD3+, CD4+, and CD30+ cells, and a smaller portion of CD8+ cells in the dermis, consistent with LCT MF. Biopsy of the axillary LN revealed diffuse sheets of CD20+, BCL‐2+, c‐MYC+, and CD10− cells, highly suggestive of double expressor DLBCL. High‐throughput sequencing revealed monoclonal T cells in the skin tumor and a monoclonal B‐cell population in the LN. The above findings led to simultaneous diagnoses of LCT MF and nodal double expressor DLBCL. Our case demonstrates the importance of performing a full pathological workup in cutaneous T‐cell lymphoma patients presenting with lymphadenopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder.
- Author
-
Wu, Susan Y., Damron, Ethan P., Xu, Jie, Fang, Penny Q., Dai, Julia, Nair, Ranjit, Malpica Castillo, Luis E., Fayad, Luis E., Torres‐Cabala, Carlos A., Medeiros, L. Jeffrey, Vega, Francisco, Miranda, Roberto N., Duvic, Madeleine, Pinnix, Chelsea C., Dabaja, Bouthaina S., Iyer, Swaminathan P., Huen, Auris O., and Gunther, Jillian R.
- Subjects
- *
CUTANEOUS T-cell lymphoma , *LYMPHOPROLIFERATIVE disorders , *T cells , *CD4 antigen , *RADIOTHERAPY , *RADIOTHERAPY complications - Abstract
Background Objective Methods Results Conclusion Primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder (PCSM‐LPD) is an increasingly recognized entity with heterogeneous management strategies that may include radiotherapy.Our aim was to characterize treatment options for PCSM‐LPD, with a focus on the role of radiotherapy.This is a retrospective review of 46 patients seen in the Cutaneous Lymphoma Program at the University of Texas MD Anderson Cancer Center, with a clinicopathologic review consistent with PCSM‐LPD. All patients were biopsied and underwent observation, topical/intralesional steroids, and/or radiotherapy. Patients were confirmed to have residual disease prior to radiotherapy.All patients achieved a complete response (CR). Sixteen patients (35%) received focal radiotherapy, with a CR in 15 (94%). The CR rate following ultra‐low‐dose radiotherapy (4 Gy in 1–2 fractions) was 92%. There was no grade 3 toxicity after radiotherapy. Thirty patients were managed without radiotherapy, with excision and observation or steroids.Primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder has excellent outcomes, and management strategies may include observation following biopsy, steroids, or radiation. Ultra‐low‐dose radiotherapy results in excellent outcomes with limited toxicity and is effective for persistent lesions after steroidal therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Myositis as a prominent manifestation of primary skeletal muscle peripheral T-cell lymphoma: a case report and literature review.
- Author
-
Jin, Zhengyi, Hu, Jiaqi, Min, Thumon, Chen, Lixia, Zhang, Fang, Kong, Ruina, and Gao, Jie
- Subjects
- *
T-cell lymphoma , *LITERATURE reviews , *SKELETAL muscle , *CUTANEOUS T-cell lymphoma , *POLYMYOSITIS , *RARE diseases , *MYOSITIS - Abstract
The patient presented to the clinic with painful muscle swelling in the right lower extremity, which improved with immunosuppressive therapy. Initially, the condition was diagnosed as polymyositis but recurred soon after. After imaging and biopsy, the final diagnosis was primary skeletal muscle peripheral T-cell lymphoma, not otherwise specified (PSM-PTCL, NOS). In this report, we discuss the challenges in diagnosing and treating this aggressive malignancy and review the literature on PSM-PTCL, NOS. Key Points • To date, there are few reports of PSM-PTCL, NOS, and our case is the tenth. • It is crucial to consider PSM-PTCL, NOS, when presenting with localized muscle edema and unexplained pain. • Histopathological examination is likely the most effective method for diagnosing this rare disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Modular Synthesis of Methyl-Substituted Novel Psoralen N -Hydroxysuccinimide Esters and Evaluation of DNA Photocrosslinking Properties of the Corresponding Triplex-Forming Oligonucleotide Conjugates.
- Author
-
Mikame, Yu, Maekawa, Nagisa, Kimura, Soichiro, Nakao, Juki, and Yamayoshi, Asako
- Subjects
- *
OLIGONUCLEOTIDES , *PHOTOCROSSLINKING , *PSORALENS , *BORON trifluoride , *DNA , *CUTANEOUS T-cell lymphoma - Abstract
This article explores the synthesis of methyl-substituted psoralen derivatives and their potential for DNA photocrosslinking. Psoralen is a natural compound used in skin disease treatment, but it can have toxic and mutagenic effects. The researchers aimed to enhance the reactivity of psoralen and control crosslinked product formation by adding methyl substituents at specific positions. They developed a synthetic method for creating psoralen derivatives and tested their photocrosslinking abilities with DNA. The results showed that the presence of methyl substituents reduced the formation of harmful diadducts. The article suggests further research to explore different psoralen derivatives and investigate their photocrosslinking properties. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
41. Preliminary Experience in Ultra-High Frequency Ultrasound Assessment of Cutaneous Primary Lymphomas: An Innovative Classification.
- Author
-
Russo, Anna, Patanè, Vittorio, Gagliardi, Federico, Urraro, Fabrizio, Ronchi, Andrea, Vitiello, Paola, Sica, Antonello, Argenziano, Giuseppe, Nardone, Valerio, and Reginelli, Alfonso
- Subjects
- *
SKIN tumors , *LYMPHOMAS , *ULTRASONIC imaging , *TUMOR grading , *COLOR Doppler ultrasonography , *LONGITUDINAL method , *CUTANEOUS T-cell lymphoma , *B cell lymphoma - Abstract
Simple Summary: Primary cutaneous lymphomas (PCLs) are rare forms of skin cancer arising from certain types of white blood cell. They affect the skin without spreading to other parts of the body initially. Understanding them is crucial as they require different treatments compared to other skin cancers. However, diagnosing PCLs is tricky because they can look similar to other skin conditions. We are proposing to use a type of ultrasound called high-frequency ultrasound (HFUS) to better understand how PCLs appear under the skin. By doing this, we hope to improve our ability to identify PCLs accurately and quickly. This could lead to better treatment decisions and outcomes for patients with PCLs. Background: Primary cutaneous lymphoma (PCL) is a rare form of extranodal non-Hodgkin's lymphoma characterized by malignant lymphocytes confined to the skin. Accurate diagnosis and staging are crucial for optimal management, yet radiological literature on imaging PCL remains limited. This study aims to delineate the imaging characteristics of PCLs using high and ultra-high frequency ultrasound (UHFUS) and proposes a classification system based on ultrasound findings. Methods: A cohort of 88 individuals with suspected PCL underwent high-resolution ultrasound (HRUS) and color Doppler examination of lesions. Lesions were categorized based on sonographic appearance, and subsequent histopathological assessment confirmed the diagnosis. Results: Ultrasound imaging revealed distinct patterns for primary cutaneous T-cell lymphomas (PCTCL) and primary cutaneous B-cell lymphomas (PCBCL), with characteristic features such as hypoechoic nodules, pseudonodular lesions, and dermal infiltration. Histopathological analysis confirmed the ultrasound findings, supporting the proposed classification system. Conclusions: Ultrasonography, particularly UHFUS, offers valuable insights into the imaging characteristics of primary cutaneous lymphomas, aiding the accurate diagnosis and assessment of treatment response. The proposed classification system based on ultrasound findings enhances the diagnostic approach to PCLs, and paves the way for improved patient care and management strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma.
- Author
-
Gordon, Max J., Dubois, Sigrid, Bryant, Bonita, Ng, Samuel, Conlon, Kevin, Miljkovic, Milos D., Waldmann, Thomas, and Roschewski, Mark
- Subjects
- *
ALEMTUZUMAB , *T-cell lymphoma , *INTERLEUKIN-15 , *SEZARY syndrome , *REGULATORY T cells , *ANTIBODY-dependent cell cytotoxicity , *KILLER cells , *CUTANEOUS T-cell lymphoma - Abstract
A phase 1 study was conducted to investigate the combination of interleukin-15 (IL-15) and avelumab in patients with relapsed or refractory T-cell lymphoma. IL-15 is known to stimulate NK and T-cell functions, and previous studies have shown that it can enhance the activity of anti-tumor monoclonal antibodies. Avelumab is an anti-PDL1 antibody that functions as an immune checkpoint inhibitor. The study enrolled eight patients, and although the maximum tolerated dose was not established due to early closure, two patients with PTCL-NOS had a partial response and two had stable disease. The results of this study can inform ongoing efforts to improve immunotherapy for T-cell lymphomas. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
43. Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing surveillance in Japan.
- Author
-
Ishitsuka, Kenji, Yasukawa, Tomoharu, and Tsuji, Yukie
- Subjects
CUTANEOUS T-cell lymphoma ,T-cell lymphoma ,CHEMOKINE receptors ,DRUG side effects ,STEM cell transplantation - Abstract
Mogamulizumab is a humanized antibody targeting CC chemokine receptor 4 (CCR4). This post‐marketing surveillance was conducted in Japan as a regulatory requirement from 2014 to 2020 to ensure the safety and effectiveness of mogamulizumab in patients with relapsed or refractory (r/r) CCR4‐positive peripheral T‐cell lymphoma (PTCL) or r/r cutaneous T‐cell lymphoma (CTCL). Safety and effectiveness data were collected for up to 31 weeks after treatment initiation. A total of 142 patients were registered; safety was evaluated in 136 patients. The median number of doses was 8.0 (range, 1–18). The main reasons for treatment termination were insufficient response (22.1%) and adverse events (13.2%). The frequency of any grade adverse drug reaction was 57.4%, including skin disorders (26.5%), infections and immune system disorders (16.2%), and infusion‐related reactions (13.2%). Graft‐versus‐host disease, grade 2, developed in one of two patients who underwent allogeneic‐hematopoietic stem cell transplantation after receiving mogamulizumab. Effectiveness was evaluated in 131 patients (103 with PTCL; 28 with CTCL). The best overall response rate was 45.8% (PTCL, 47.6%; CTCL, 39.3%). At week 31, the survival rate was 69.0% (95% confidence interval, 59.8%–76.5%) [PTCL, 64.4% (54.0%–73.0%); CTCL, 90.5% (67.0%–97.5%)]. Safety and effectiveness were comparable between patients <70 and ≥ 70 years old and between those with relapsed and refractory disease. The safety and effectiveness of mogamulizumab for PTCL and CTCL in the real world were comparable with the data reported in previous clinical trials. Clinical Trial Registration [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Progressive Eyelash Loss and Scale of the Right Eyelid.
- Author
-
Wondimu, Bitania and Shinohara, Michi
- Subjects
ALOPECIA areata ,DRUG eruptions ,CUTANEOUS T-cell lymphoma ,T-cell receptor genes ,T helper cells ,MEDICAL communication - Abstract
This article discusses a case of progressive eyelash loss and scale on the right eyelid in an 88-year-old man. The diagnosis was folliculotropic mycosis fungoides (FMF), a variant of mycosis fungoides (MF) characterized by folliculotropism and follicular-based lesions. FMF can present with various clinical manifestations, including patches, plaques, tumors, acneform lesions, and areas of alopecia. The article also mentions other differential diagnoses such as alopecia mucinosa, seborrheic dermatitis, and alopecia areata. The document provides information on different types of hair loss conditions, including patchy alopecia and psoriatic alopecia, and discusses their histopathologic features and immunohistochemistry findings. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
45. Alopecia areata-like presentations with mogamulizumab therapy
- Author
-
Kincaid, Colin M, Sharma, Ajay N, Lee, Bonnie A, Pinter-Brown, Lauren C, Smith, Janellen, Linden, Kenneth, and Mesinkovska, Natasha A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Sézary syndrome ,alopecia ,alopecia areata ,cutaneous T-cell lymphoma ,drug rash ,hair loss ,mogamulizumab ,mycosis fungoides ,Clinical sciences - Published
- 2023
46. Compatibility study of topical 0.25% hypericin (HyBryteTM) application in subjects with mycosis fungoides: Results of the HPN‐CTCL‐02 study
- Author
-
Carolina V. Alexander‐Savino, Adam Rumage, Christopher Pullion, Richard Straube, Christopher J. Schaber, Elaine S. Gilmore, and Brian Poligone
- Subjects
CTCL ,cutaneous T‐cell lymphoma ,electrocardiogram changes ,photodynamic therapy ,pharmacokinetic ,topical hypericin ,Dermatology ,RL1-803 ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Background HyBryteTM is a photodynamic therapy of topical hypericin that has recently been shown to be safe and efficacious in early stage cutaneous T‐cell lymphoma (CTCL). However, its efficacy, absorption, and effect on heart function parameters in patients who require greater HyBryteTM exposure is unknown. Objectives The primary objectives in this study were to assess hypericin blood levels using a validated detection method with a cut‐off value of 0.05 ng/mL and to determine if topical HyBryteTM induces any electrocardiogram (EKG) changes during 8 weeks of treatment. A secondary endpoint of this study was to assess the effectiveness of HyBryteTM in this patient population as well as assessing a different additional light device than the one used in the Phase 3 HPN‐CTCL‐01/fluorescent light activated synthetic hypericin trial also entitled “A phase 3 multicenter randomised placebo‐controlled study to determine the efficacy of topical hypericin and light irradiation for the treatment of cutaneous T‐cell lymphoma”. Methods A confirmatory, prospective, open‐label, single‐centre, interventional study focused on stage IB and IIA mycosis fungoides with more than 10% of their body surface areas involved was performed. Results Hypericin concentration in K2EDTA whole blood samples collected before and after light activation at Weeks 4, 6 and 8 showed an average blood concentration of 0.13 ng/mL and achieved steady state by Week 4. EKGs were examined for clinical changes at each study visit, including changes in QT intervals and correction of heart rates. No significant clinical changes in EKGs were observed. Conclusions Hypericin does not appear to be significantly absorbed through the skin nor cause significant cardiac changes overall or prolong the QT interval when applied topically. A larger study is necessary to clearly define these results.
- Published
- 2024
- Full Text
- View/download PDF
47. Concurrent papular and dyshidrotic mycosis fungoides: A case report in a patient with skin of color
- Author
-
Bryan Ma, MD, Brian D. Rankin, MD, PhD, Melissa Yanitski, RN, Xiu Y. Jiang, MD, Lesley Street, MD, and Jori Hardin, MD
- Subjects
cutaneous T-cell lymphoma ,dyshidrotic mycosis fungoides ,mycosis fungoides ,papular mycosis fungoides ,skin of color ,Dermatology ,RL1-803 - Published
- 2024
- Full Text
- View/download PDF
48. A unique case of paraneoplastic lymphomatoid Papuloerythroderma of Ofuji with atypical clinical features
- Author
-
Oluwaseyi Adeuyan, BS, Megan H. Trager, MD, Emily R. Gordon, BA, Brigit A. Lapolla, BS, Celine M. Schreidah, BS, Lauren M. Fahmy, BS, Caroline Chen, BA, Cynthia M. Magro, MD, and Larisa J. Geskin, MD
- Subjects
cutaneous T-cell lymphoma ,dupilumab ,hypereosinophilic syndrome ,lymphoid reaction ,Papuloerythroderma of Ofuji ,paraneoplastic ,Dermatology ,RL1-803 - Published
- 2024
- Full Text
- View/download PDF
49. A clinical case report on Mycosis Fungoides
- Author
-
Isabella Raffa, Jose Mendez, Sultan Ahmed, Syed Rizvi, Syed Imam, and Nada Saleh
- Subjects
skin rash ,mycosis fungoides ,cutaneous t-cell lymphoma ,Medicine - Abstract
Background and Objectives: This case report highlights an aggressive and resistant biological course in a patient with mycosis fungoides, which resulted in a poor prognosis despite multiple therapies. The patient ultimately required aggressive chemotherapy due to systemic involvement.Case Presentation: A 64-year-old Hispanic male presented to the dermatology clinic for evaluation of hardened, erythematous lesions distributed across his trunk and upper extremities, accompanied by generalized pruritus. He reported that the lesions had been present for approximately two years and had increased in size over time. Pathology results from punch biopsies taken from the lesions confirmed a diagnosis of mycosis fungoides. Treatment with topical glucocorticoids and systemic retinoids was initiated; however, after six months, the disease progressed to involve lymph nodes. The patient underwent multiple rounds of radiation therapy for advanced lesions and was subsequently referred to an oncologist for further treatment due to the poor prognosis.Discussion: Mycosis fungoides is a form of T-cell lymphoma that is typically confined to the cutaneous tissue. A high expression of CD30+ lymphocytes in the epidermis is indicative of transformation into advanced large cell lymphoma, suggesting an aggressive clinical course and an overall poor prognosis. While mycosis fungoides is generally considered a low-grade, indolent malignancy, this case demonstrates an aggressive and resistant biological course, leading to a significantly poorer outcome.
- Published
- 2024
- Full Text
- View/download PDF
50. Atypical presentation of γ/δ mycosis fungoides with an unusual phenotype and SOCS1 mutation
- Author
-
Nielsen Pia Rude, Schejbel Lone, Josefsson Pär Lars, Skov Lone, and Nielsen Signe Ledou
- Subjects
cutaneous t-cell lymphoma ,mycosis fungoides ,immunophenotypic ,gamma/delta phenotype ,Biology (General) ,QH301-705.5 - Abstract
Mycosis fungoides is the most frequent subtype of primary cutaneous T-cell lymphomas. The diagnosis is based on a thorough clinic-pathologic correlation, which can, especially in early-stage disease, be challenging due to similarities with several benign skin disorders such as psoriasis and atopic dermatitis. Here, we present a case of an 81-year-old man with a 20-year-long medical history of skin problems treated as psoriasis with limited effect. Since December 2021, the patient experienced worsening of his skin symptoms with rapidly growing tumors and widespread patches and plaques. Positron emission tomography/computed tomography evaluation revealed markedly metabolic activity related to the skin tumors and increased FDG uptake in several retroperitoneal lymph nodes. Histological assessment of skin biopsies demonstrated a highly proliferative T-cell lymphoma with a γ/δ+ and CD8+ cytotoxic phenotype. The morphology of the tumor cells appeared blastic with an abnormal immunephenotype CD3+, CD2−, CD5dim, CD4−, CD8+, CD56−, and CD30−. Next-generation sequencing detected a likely pathogenic SOCS1 mutation with an allele frequency of 72% as well as a STAT3 variant of unknown significance. This case highlights the diagnostic complexity of an indolent skin lymphoma evolving into an aggressive cytotoxic lymphoma.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.